Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study
Por:
Mercader-Garcia, P, Pastor-Nieto, MA, Gonzalez-Perez, R, Cordoba-Guijarro, S, Gimenez-Arnau, AM, Ruiz-Gonzalez, I, Mora-Fernandez, V, Miquel, J, Silvestre-Salvador, JF, Ortiz-Frutos, FJ, Sanz-Sanchez, T, Rodriguez-Serna, M, Perez-Feal, P, Sanchez-Perez, J, Heras-Mendaza, F, Serra-Baldrich, E, Zaragoza-Ninet, V, Hervella-Garces, M, Gatica-Ortega, ME, Garcia-Doval, I, Descalzo, MA, Borrego, L
Publicada:
1 nov 2021
Resumen:
Background Methyldibromo glutaronitrile (MDBGN) was one of the most frequent and relevant allergens found in patch testing at the beginning of this century. In 2008, this preservative was banned from cosmetics in Europe and ever since the prevalence of contact allergy to MDBGN has progressively decreased. Despite that gradual decline, MDBGN is still patch-tested in most baseline series. This study assessed the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients, and the relevance of positive patch tests in a nationwide Spanish registry (REIDAC). Patients and methods We evaluated consecutively patch-tested patients in all participating centres. Using these data, we calculated the proportion of patients with positive patch tests to MDBGN from June 2018 to June 2020 and evaluated the relevance of the positive patch tests. Results One hundred and fourteen out of 5072 (2.24 %) tested patients were sensitized to MDBGN. Clinical current relevance was confirmed in only one case. Conclusion Although the frequency of contact allergy to MDBGN remains high, no clinical significance was found in most of these patients (5072 tests needed to obtain one relevant positive result). The clinical usefulness of this allergen seems weak and its continued inclusion in the European baseline series is questionable.
Filiaciones:
Mercader-Garcia, P:
Univ Jose M Morales Meseguer, Hosp Gen, Dept Dermatol, Murcia, Spain
Pastor-Nieto, MA:
Univ Guadalajara, Hosp Gen, Dept Dermatol, Guadalajara, Spain
Gonzalez-Perez, R:
Hosp Univ Araba, Dept Dermatol, Vitoria, Spain
Cordoba-Guijarro, S:
Hosp Univ Fuenlabrada, Dept Dermatol, Fuenlabrada, Spain
Gimenez-Arnau, AM:
Hosp Mar IMAS, Dept Dermatol, Barcelona, Spain
Ruiz-Gonzalez, I:
Complejo Asistencial Univ Leon, Dept Dermatol, Leon, Spain
Mora-Fernandez, V:
Univ German Trias & Pujol, Hosp Gen, Dept Dermatol, Barcelona, Spain
Miquel, J:
Hosp Arnau Vilanova, Dept Dermatol, Valencia, Spain
Silvestre-Salvador, JF:
Hosp Gen Univ, Dept Dermatol, Alicante, Spain
Ortiz-Frutos, FJ:
Univ 12 Octubre, Hosp Gen, Dept Dermatol, Madrid, Spain
Sanz-Sanchez, T:
Univ Infanta Sofia, Hosp Gen, Dept Dermatol, Madrid, Spain
Rodriguez-Serna, M:
Univ La Fe, Hosp Gen, Dept Dermatol, Valencia, Spain
Perez-Feal, P:
Univ Santiago Compostela, Complejo Hosp, Dept Dermatol, Santiago De Compostela, Spain
Sanchez-Perez, J:
Hosp Univ La Princesa, Dept Dermatol, Madrid, Spain
Heras-Mendaza, F:
Hosp Fdn Jimenez Diaz, Dept Dermatol, Madrid, Spain
Serra-Baldrich, E:
Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
Zaragoza-Ninet, V:
Univ Valencia, Consorcio Hosp Gen, Dept Dermatol, Valencia, Spain
Hervella-Garces, M:
Complejo Hosp Navarra, Dept Dermatol, Pamplona, Spain
Gatica-Ortega, ME:
Complejo Hosp Toledo, Dept Dermatol, Toledo, Spain
Garcia-Doval, I:
Acad Espanola Dermatol & Venereol, Fdn Piel Sana, Res Unit, Madrid, Spain
Descalzo, MA:
Acad Espanola Dermatol & Venereol, Fdn Piel Sana, Res Unit, Madrid, Spain
Borrego, L:
Univ Las Palmas Gran Canaria, Univ Insular Materno Infantil, Complejo Hosp, Dept Dermatol, Las Palmas Gran Canaria, Spain
Green Published
|